Mechanisms of endothelial dysfunction in resistance arteries from patients with end-stage renal disease

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Luksha, Leanid ^a   Stenvinkel, Peter ^a   Hammarqvist, Folke ^a   Carrero, Juan Jesús ^a   Davidge, Sandra T ^b   Kublickiene, Karolina ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; BRADYKININ; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; KININ RECEPTOR; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NITRIC OXIDE DONOR; PINACIDIL; UNCLASSIFIED DRUG; ARGININE; BIOLOGICAL FACTOR; DIMETHYLARGININE; DRUG DERIVATIVE; ENDOTHELIUM DEPENDENT HYPERPOLARIZATION FACTOR; ENDOTHELIUM-DEPENDENT HYPERPOLARIZATION FACTOR; VASODILATOR AGENT;

ADULT; ARTERY; ARTERY DILATATION; ARTERY TONE; ARTICLE; CELL JUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY FAILURE; MALE; MYOENDOTHELIAL GAP JUNCTION; PROTEIN EXPRESSION; RESISTANCE ARTERY; RESISTANCE BLOOD VESSEL; SMOOTH MUSCLE; SUBCUTANEOUS FAT; UREMIA; AGED; BLOOD; CHRONIC KIDNEY FAILURE; DRUG EFFECT; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM;

ADULT; AGED; ARGININE; ARTERIES; BIOLOGICAL FACTORS; BRADYKININ; ENDOTHELIUM, VASCULAR; FEMALE; GAP JUNCTIONS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE III; VASODILATOR AGENTS;

EID: 84860370732     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036056     Document Type: Article

References (45)

1. Stenvinkel P, Pecoits-Filho R, Lindholm B, (2003) Coronary Artery Disease in End-Stage Renal Disease: No Longer a Simple Plumbing Problem. J Am Soc Nephrol 14: 1927-1939.
2. Schiffrin EL, Lipman ML, Mann JF, (2007) Chronic Kidney Disease: Effects on the Cardiovascular System. Circulation 116: 85-97.
3. Brocq ML, Leslie SJ, Milliken P, Megson I, (2008) Endothelial Dysfunction: From Molecular Mechanisms to Measurement, Clinical Implications, and Therapeutic Opportunities. Antioxid Redox Signal 10: 1631-1674.
4. Chhabra N, (2009) Endothelial dysfunction - A predictor of atherosclerosis. Internet J Med Update 4: 33-41.
5. Félétou M, Köhler R, Vanhoutte P, (2010) Endothelium-derived Vasoactive Factors and Hypertension: Possible Roles in Pathogenesis and as Treatment Targets. Curr Hypertens Rep 12: 267-275.
6. Vettoretti S, Ochodnicky P, Buikema H, Henning RH, Kluppel CA, et al. (2006) Altered myogenic constriction and endothelium-derived hyperpolarizing factor-mediated relaxation in small mesenteric arteries of hypertensive subtotally nephrectomized rats. J Hypertens 24: 2215-2223.
7. Malyszko JS, Malyszko J, Hryszko T, Kozminski P, Pawlak K, et al. (2006) Markers of endothelial damage in patients on hemodialysis and hemodiafiltration. J Nephrol 19: 150-154.
8. Yilmaz MI, Saglam M, Carrero JJ, Qureshi AR, Caglar K, et al. (2008) Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol Dial Transplant 23: 959-965.
9. Morris S, McMurray J, Spiers A, Jardine AG, (2001) Impaired endothelial function in isolated human uremic resistance arteries. Kidney Int 60: 1077-1082.
10. Passauer J, Pistrosch F, Lässig G, Herbrig K, Büssemaker E, et al. (2005) Nitric oxide- and EDHF-mediated arteriolar tone in uremia is unaffected by selective inhibition of vascular cytochrome P450 2C9. Kidney Int 67: 1907-1912.
11. Luksha N, Luksha L, Carrero JJ, Hammarqvist F, Stenvinkel P, et al. (2011) Impaired resistance artery function in patients with end-stage renal disease. Clin Sci (Lond) 120: 525-536.
12. Baylis C, (2008) Nitric oxide deficiency in chronic kidney disease. Am J Physiol Renal Physiol 294: F1-9.
13. Luksha L, Agewall S, Kublickiene K, (2009) Endothelium-derived hyperpolarizing factor in vascular physiology and cardiovascular disease. Atherosclerosis 202: 330-344.
14. Benchetrit S, Green J, Katz D, Bernheim J, Rathaus M, (2003) Early endothelial dysfunction following renal mass reduction in rats. Eur J Clin Invest 33: 26-33.
15. Kohler R, Eichler I, Schonfelder H, Grgic I, Heinau P, et al. (2005) Impaired EDHF-mediated vasodilation and function of endothelial Ca2+-activated K+-channels in uremic rats. Kidney Int 67: 2280-2287.
16. Kalliovalkama J, Jolma P, Tolvanen J-P, Kähönen M, Hutri-Kähönen N, et al. (1999) Potassium channel-mediated vasorelaxation is impaired in experimental renal failure. Am J Physiol Heart Circ Physiol 277: H1622-H1629.
17. Kimura K, Nishio I, (1999) Impaired endothelium-dependent relaxation in mesenteric arteries of reduced renal mass hypertensive rats. Scand J Clin Lab Invest 59: 199-204.
18. Gschwend S, Haug MB, Nierhaus M, Schulz A, Vetter R, et al. (2009) Short-term treatment with a beta-blocker with vasodilative capacities improves intrarenal endothelial function in experimental renal failure. Life Sci 85: 431-437.
19. Passauer J, Pistrosch F, Büssemaker E, Lässig G, Herbrig K, et al. (2005) Reduced Agonist-Induced Endothelium-Dependent Vasodilation in Uremia Is Attributable to an Impairment of Vascular Nitric Oxide. J Am Soc Nephrol 16: 959-965.
20. Sokoya EM, Burns AR, Marrelli SP, Chen J, (2007) Myoendothelial gap junction frequency does not account for sex differences in EDHF responses in rat MCA. Microvascular Research 74: 39-44.
21. Prasad A, Husain S, Schenke W, Mincemoyer R, Epstein N, et al. (2000) Contribution of bradykinin receptor dysfunction to abnormal coronary vasomotion in humans. J Am Coll Cardiol 36: 1467-1473.
22. Wirth KJ, Linz W, Wiemer G, Schölkens BA, (1996) Differences in acetylcholine- and bradykinin-induced vasorelaxation of the mesenteric vascular bed in spontaneously hypertensive rats of different ages. Naunyn Schmiedebergs Arch Pharmacol 354: 38-43.
23. Pascoal IF, Lindheimer MD, Nalbantian-Brandt C, Umans JG, (1998) Preeclampsia selectively impairs endothelium-dependent relaxation and leads to oscillatory activity in small omental arteries. J Clin Invest 101: 464-470.
24. Luksha L, Luksha N, Kublickas M, Nisell H, Kublickiene K, (2010) Diverse Mechanisms of Endothelium-Derived Hyperpolarizing Factor-Mediated Dilatation in Small Myometrial Arteries in Normal Human Pregnancy and Preeclampsia. Biol Reprod 83: 728-735.
25. Luksha L, Nisell H, Luksha N, Kublickas M, Hultenby K, et al. (2008) Endothelium-derived hyperpolarizing factor in preeclampsia: heterogeneous contribution, mechanisms, and morphological prerequisites. Am J Physiol Regul Integr Comp Physiol 294: R510-R519.
26. Kühberger E, Kukovetz WR, Groschner K, (1993) Cromakalim Inhibits Multiple Mechanisms of Smooth Muscle Activation with Similar Stereoselectivity. J Cardiovasc Pharmacol 21: 947-954.
27. Stojnic N, Gojkovic-Bukarica L, Peric M, Grbovic L, Lesic A, et al. (2007) Potassium channel opener pinacidil induces relaxation of the isolated human radial artery. J Pharmacol Sci 104: 122-129.
28. Deka DK, Raviprakash V, Mishra SK, (1998) Basal nitric oxide release differentially modulates vasodilations by pinacidil and levcromakalim in goat coronary artery. Eur J Pharmacol 348: 11-23.
29. Rees DD, Palmer RM, Moncada S, (1989) Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci USA 86: 3375-3378.
30. Passauer J, Bussemaker E, Range U, Plug M, Gross P, (2000) Evidence In Vivo Showing Increase of Baseline Nitric Oxide Generation and Impairment of Endothelium-Dependent Vasodilation in Normotensive Patients on Chronic Hemodialysis. J Am Soc Nephrol 11: 1726-1734.
31. Kao M, Ang D, Pall A, Struthers AD, (2009) Oxidative stress in renal dysfunction: mechanisms, clinical sequelae and therapeutic options. J Hum Hypertens 24: 1-8.
32. Kim SW, Lee JU, Paek YW, Kang DG, Choi KC, (2000) Decreased nitric oxide synthesis in rats with chronic renal failure. J Korean Med Sci 15: 425-430.
33. Bonomini M, Pandolfi A, Pietro ND, Sirolli V, Giardinelli A, et al. (2005) Adherence of uremic erythrocytes to vascular endothelium decreases endothelial nitric oxide synthase expression. Kidney Int 67: 1899-1906.
34. Linden E, Cai W, He JC, Xue C, Li Z, et al. (2008) Endothelial Dysfunction in Patients with Chronic Kidney Disease Results from Advanced Glycation End Products-Mediated Inhibition of Endothelial Nitric Oxide Synthase through RAGE Activation. Clin J Am Soc Nephrol 3: 691-698.
35. Gómez-Fernández P, Pérez-Requena J, Sánchez-Margalet V, Esteban J, Murillo-Carretero M, et al. (2005) Vascular damage in chronic renal failure. The increase of vascular nitrotyrosine and cytochines accumulation is accompanied by an increase of endothelial nitric oxide synthase expression. Nefrologia 25: 155-162.
36. Billecke SS, D'Alecy LG, Platel R, Whitesall SE, Jamerson KA, et al. (2009) Blood content of asymmetric dimethylarginine: new insights into its dysregulation in renal disease. Nephrol Dial Transplant 24: 489-496.
37. Antoniades C, Shirodaria C, Leeson P, Antonopoulos A, Warrick N, et al. (2009) Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: implications for endothelial function in human atherosclerosis. European Heart Journal 30: 1142-1150.
38. Veresh Z, Racz A, Lotz G, Koller A, (2008) ADMA Impairs Nitric Oxide-Mediated Arteriolar Function Due to Increased Superoxide Production by Angiotensin II-NAD(P)H Oxidase Pathway. Hypertension 52: 960-966.
39. Satoh M, Fujimoto S, Arakawa S, Yada T, Namikoshi T, et al. (2008) Angiotensin II type 1 receptor blocker ameliorates uncoupled endothelial nitric oxide synthase in rats with experimental diabetic nephropathy. Nephrology Dialysis Transplantation 23: 3806-3813.
40. Satoh M, Fujimoto S, Haruna Y, Arakawa S, Horike H, et al. (2005) NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. American Journal of Physiology- Renal Physiology 288: F1144-F1152.
41. Yilmaz MI, Saglam M, Caglar K, Cakir E, Ozgurtas T, et al. (2005) Endothelial Functions Improve with Decrease in Asymmetric Dimethylarginine Levels after Renal Transplantation. Transplantation 80: 1660-1666.
42. Mittermayer F, Schaller G, Pleiner J, Vychytil A, Sunder-Plassmann G, et al. (2005) Asymmetrical Dimethylarginine Plasma Concentrations Are Related to Basal Nitric Oxide Release but Not Endothelium-Dependent Vasodilation of Resistance Arteries in Peritoneal Dialysis Patients. J Am Soc Nephrol 16: 1832-1838.
43. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, et al. (2003) Asymmetric Dimethylarginine Causes Hypertension and Cardiac Dysfunction in Humans and Is Actively Metabolized by Dimethylarginine Dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 23: 1455-1459.
44. Albrecht E, van Goor H, Smit-van Oosten A, Stegeman C, (2003) Long-term dietary-arginine supplementation attenuates proteinuria and focal glomerulosclerosis in experimental chronic renal transplant failure. Nitric Oxide 8: 53-58.
45. Wadham C, Mangoni AA, (2009) Dimethylarginine dimethylaminohydrolase regulation: a novel therapeutic target in cardiovascular disease. Expert Opin Drug Metab Toxicol 5: 303-319.